e-learning
resources
Madrid 2019
Wednesday, 02.10.2019
Exacerbations and clinical impact of airway diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD
H. Hoch (Aurora, United States of America), R. Gondalia (San Francisco, United States of America), W. Anderson (Aurora, United States of America), M. Barrett (San Francisco, United States of America), S. Szefler (Aurora, United States of America), D. Van Sickle (Madison, United States of America), D. Stempel (San Francisco, United States of America)
Source:
International Congress 2019 – Exacerbations and clinical impact of airway diseases
Session:
Exacerbations and clinical impact of airway diseases
Session type:
Oral Presentation
Number:
5350
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Hoch (Aurora, United States of America), R. Gondalia (San Francisco, United States of America), W. Anderson (Aurora, United States of America), M. Barrett (San Francisco, United States of America), S. Szefler (Aurora, United States of America), D. Van Sickle (Madison, United States of America), D. Stempel (San Francisco, United States of America). Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD. 5350
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Nighttime short-acting beta-agonist (SABA) in asthma and COPD
Source: International Congress 2019 – Impact of sleep-disordered breathing in other diseases
Year: 2019
Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence?
Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents?
Year: 2020
Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
Overuse of short-acting beta-agonists (SABA) and risk factors among patients with asthma
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020
First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients?
Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids
Year: 2004
Combination of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA)
versus
similar ICS dose in children and adults with persistent asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005
Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004
Is the combination of long-acting β
2
-agonists (LABA) and inhaled steroids (ICS) superior to higher ICS dose in children and adults with persistent asthma?
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005
Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma
Source: International Congress 2017 – Techniques to treat asthma
Year: 2017
The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA)
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012
SABA use increase weeks before asthma exacerbations recorded via a digital inhaler
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
Efficacy of indacaterol in COPD is maintained irrespective of inhaled corticosteroid (ICS) use
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
A digital inhaler uncovering patterns of SABA use in asthma and COPD
Source: Virtual Congress 2020 – Digital health interventions in respiratory medicine
Year: 2020
Concomitant use of long-acting beta-agonists with inhaled corticosteroids among asthma patients in the UK primary care
Source: Annual Congress 2007 - Miscellaneous epidemiological aspects of respiratory disease
Year: 2007
Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization
Source: Annual Congress 2011 - Airways disease comorbidities and general aspects
Year: 2011
Predictors of excessive short-acting beta2-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020
Inhaled corticosteroid combined with long-acting bronchodilator versus long-acting bronchodilator alone for older patients with COPD
Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation
Year: 2015
Use of short-acting beta-2 agonists (SABA) and exacerbations in a nationwide Swedish asthma cohort (HERA)
Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies
Year: 2019
Salmeterol/fluticasone combination (SFC) is associated with improved asthma control compared with concurrent long-acting β
2
agonists (LABA) and inhaled corticosteroids (ICS) or ICS alone
Source: Eur Respir J 2003; 22: Suppl. 45, 235s
Year: 2003
A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD
Source: Annual Congress 2013 –Risk factors for COPD and lung function decline
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept